The Kamphorst lab focuses on T cell differentiation with a specific interest on situations of chronic antigen stimulation, such as in cancer. The research program aims to determine how inflammation, costimulation and other factors in the microenvironment influence CD8 T cell differentiation, dysfunction and rescue by immunotherapy. We study the interplay of different signaling pathways with the PD-1 (programmed cell death-1) pathway. To address those questions the lab uses mouse models of chronic viral infection and tumor, as well as analysis of samples from cancer patients. The lab has a deep interest on how adaptive immune responses are modulated and on interventional strategies that can be used to improve human health. Understanding the factors that govern T cell differentiation and function will enable the identification of targetable molecules and pathways to improve the efficacy of immunotherapy.
PhD, Rockefeller University
Postdoc, Emory University
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Silva(Kamphorst) during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Silva(Kamphorst) during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.